摘要
目的了解口服血管生成抑制剂参一胶囊联合化疗对非小细胞肺癌术后生存的影响。方法采用前瞻性随机病例对照研究方法对90例非小细胞肺癌(Ⅱ～ⅢA期)根治术后患者随机分为口服参一胶囊联合化疗组(观察组)和单纯化疗组(对照组),比较两组生存期差异。结果观察组和对照组年生存率差异:1年生存率分别为82.6%、79.5%;2年生存率分别为71.7%、70.5%;3年生存率分别为54.3%、47.7%,但无统计学差异。结论非小细胞肺癌根治术后参一胶囊联合化疗可以提高患者生存,值得大样本量进一步观察研究。
Objective To explore effect of Shenyi capsule combined with chemotherapy for the post - operation patients with NSCLC. Methods Ninty cases were randomly divided into 2 groups;One was defined as observed group where they were administered Shenyi capsule combined with chemotherapy, Another group were treated with only chemotherapy. Their survival date was compared in the two group. Results The difference of year survival rate in observed group and control group： 1 year survival rate were respectively 82.6% VS 79.5% ;2 year survival rate were respectively 71.7% VS 70.5% ;3 year survival rate were respectively 54.3% VS 47.7% , however there were no significant difference in two groups （P 〉 0.05 ）. Conclusions Shenyi capsule combined with chemotherapy can improve patients survival with NSCLC after operation.
出处
《医学信息（手术学分册）》
2008年第10期897-898,共2页
Medical Information Operations Sciences Fascicule
